The VA-IMPACT (NCT02915198) is ongoing to evaluate the effect of metformin on the prevention of cardiovascular events in patients with impaired glucose tolerance and established cardiovascular disease, but at the moment, the strength of evidence of metformin as a drug to prevent ORCVD may be inferior to GLP-1RAs
Practical Meal Strategies to Meet Protein Goals on Semaglutide Many patients on GLP-1 therapy report that eating large meals becomes uncomfortable, so eating smaller amounts more frequently works better than traditional three-meal days
And that is encouraging. Among the adolescents who took the placebo drug, 19% lost enough weight to decrease their BMI by one category and 12.1% of which lost enough weight to no longer be classed as clinically obese
Metabolic Health Improvements Both medications improve metabolic markers beyond just weight loss: Reduced hemoglobin A1C (blood sugar control marker) Improved cholesterol and triglyceride levels Lower blood pressure Reduced liver fat (important for fatty liver disease) Improved insulin sensitivity Some studies suggest tirzepatide may provide slightly greater improvements in these markers, though both are highly effective
1H79TI088037 from Substance Abuse and Mental Health Services Administration (SAMHSA)
